FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
WOOD Grand Rapids on MSN4d
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Scripps News on MSN8d
FDA approves standalone nasal spray to treat depression
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
FDA approves Spravato nasal spray as a standalone treatment for depression in adults
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
Finanznachrichten9d
Johnson & Johnson Stock: FDA Approval Boosts Depression Treatment Success
Johnson & Johnson has achieved a significant milestone in depression treatment as the FDA granted expanded approval for Spravato as a monotherapy for treatment-resistant depression.
Medical News Today4d
FDA-approved nasal spray for severe depression can lead to remission
Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.